Immunogenicity and Safety of Heterologous Versus Homologous Prime-boost Schedules with an Adenoviral Vectored and MRNA COVID-19 Vaccine: a Systematic Review

Overview

Journal Infect Dis Poverty

Publisher Biomed Central

Date 2022 May 13

PMID 35562753

Authors

Jingjing Lv

Hui Wu

Junjie Xu

Jiaye Liu

Affiliations

Soon will be listed here.

Abstract

Background: Heterologous prime-boost with ChAdOx1 nCoV-19 vector vaccine (ChAd) and a messenger RNA vaccine (BNT or mRNA-1273) has been widely facilitating mass coronavirus disease 2019 (COVID-19) immunisation. This review aimed to synthesize immunogenicity and reactogenicity of heterologous immunisations with ChAd and BNT (mRNA-1273) vaccine compared with homologous ChAd or BNT (mRNA-1273) immunisation.

Methods: PubMed, Web of Science, and Embase databases were searched from inception to March 7, 2022. Immunogenicity involving serum antibodies against different SAS-CoV-2 fragments, neutralizing antibody, or spike-specific T cells response were compared. Any, local and systemic reactions were pooled by meta-analysis for comparison.

Results: Of 14,571 records identified, 13 studies (3024 participants) were included for analysis. Compared with homologous BNT/BNT vaccination, heterologous ChAd/BNT schedule probably induced noninferior anti-spike protein while higher neutralizing antibody and better T cells response. Heterologous ChAd/BNT (mRNA-1273) immunisation induced superior anti-spike protein and higher neutralizing antibody and better T cells response compared with homologous ChAd/ChAd vaccination. Heterologous ChAd/BNT (mRNA-1273) had similar risk of any reaction (RR = 1.30, 95% CI: 0.86-1.96) while higher risk of local reactions (RR = 1.65, 95% CI: 1.27-2.15) and systemic reactions (RR = 1.49, 95% CI: 1.17-1.90) compared with homologous ChAd/ChAd vaccination. There was a higher risk of local reactions (RR = 1.16, 95% CI: 1.03-1.31) in heterologous ChAd/BNT (mRNA-1273) vaccination compare with homologous BNT/BNT but a similar risk of any reaction (RR = 1.03, 95% CI: 0.79-1.34) and systemic reactions (RR = 0.89, 95% CI: 0.60-1.30).

Conclusions: Heterologous ChAd/BNT schedule induced at least comparable immunogenicity compared with homologous BNT/BNT and better immunogenicity compared with homologous ChAd/ChAd vaccination. The synthetical evidence supported the general application of heterologous prime-boost vaccination using ChAd and BNT COVID-19 vaccines.

Citing Articles

Sequential Immunization with Vaccines Based on SARS-CoV-2 Virus-like Particles Induces Broadly Neutralizing Antibodies.

Mi Y, Xu K, Wang W, Kong W, Xu X, Rong X Vaccines (Basel). 2024; 12(8).

PMID: 39204050 PMC: 11359007. DOI: 10.3390/vaccines12080927.

A single-dose intranasal live-attenuated codon deoptimized vaccine provides broad protection against SARS-CoV-2 and its variants.

Liu X, Ng W, Zusinaite E, Freitas J, Taylor A, Yerragunta V Nat Commun. 2024; 15(1):7225.

PMID: 39187479 PMC: 11347628. DOI: 10.1038/s41467-024-51535-y.

A Response to: A Letter to the Editor Regarding 'Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework'.

Beck E, Bausch-Jurken M, Van de Velde N, Wang X, Malmenas M Infect Dis Ther. 2024; 13(10):2195-2202.

PMID: 39180646 PMC: 11416437. DOI: 10.1007/s40121-024-01020-2.

Equal Maintenance of Anti-SARS-CoV-2 Antibody Levels Induced by Heterologous and Homologous Regimens of the BNT162b2, ChAdOx1, CoronaVac and Ad26.COV2.S Vaccines: A Longitudinal Study Up to the 4th Dose of Booster.

do Nascimento T, Nogami P, de Oliveira C, Neto W, da Silva C, Ribeiro A Vaccines (Basel). 2024; 12(7).

PMID: 39066430 PMC: 11281708. DOI: 10.3390/vaccines12070792.

Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination - kinetics of plasma antibodies, plasmablasts and memory B cells.

Wietschel K, Fechtner K, Antileo E, Abdurrahman G, Drechsler C, Makuvise M Front Immunol. 2024; 15:1382911.

PMID: 38807606 PMC: 11130424. DOI: 10.3389/fimmu.2024.1382911.

References

Barda N, Dagan N, Cohen C, Hernan M, Lipsitch M, Kohane I . Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021; 398(10316):2093-2100. PMC: 8555967. DOI: 10.1016/S0140-6736(21)02249-2. View

Tenbusch M, Schumacher S, Vogel E, Priller A, Held J, Steininger P . Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. Lancet Infect Dis. 2021; 21(9):1212-1213. PMC: 8321428. DOI: 10.1016/S1473-3099(21)00420-5. View

Tanriover M, Doganay H, Akova M, Guner H, Azap A, Akhan S . Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021; 398(10296):213-222. PMC: 8266301. DOI: 10.1016/S0140-6736(21)01429-X. View

Hammerschmidt S, Bosnjak B, Bernhardt G, Friedrichsen M, Ravens I, Dopfer-Jablonka A . Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination. Cell Mol Immunol. 2021; 18(10):2455-2456. PMC: 8381713. DOI: 10.1038/s41423-021-00755-z. View

Liu X, Shaw R, Stuart A, Greenland M, Aley P, Andrews N . Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021; 398(10303):856-869. PMC: 8346248. DOI: 10.1016/S0140-6736(21)01694-9. View

Bruxvoort K, Sy L, Qian L, Ackerson B, Luo Y, Lee G . Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. BMJ. 2021; 375:e068848. PMC: 8671836. DOI: 10.1136/bmj-2021-068848. View

Shahidsales S, Aledavood S, Joudi M, Molaie F, Esmaily H, Javadinia S . COVID-19 in cancer patients may be presented by atypical symptoms and higher mortality rate, a case-controlled study from Iran. Cancer Rep (Hoboken). 2021; 4(5):e1378. PMC: 8250318. DOI: 10.1002/cnr2.1378. View

Schultz N, Sorvoll I, Michelsen A, Munthe L, Lund-Johansen F, Ahlen M . Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021; 384(22):2124-2130. PMC: 8112568. DOI: 10.1056/NEJMoa2104882. View

Hillus D, Schwarz T, Tober-Lau P, Vanshylla K, Hastor H, Thibeault C . Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir Med. 2021; 9(11):1255-1265. PMC: 8360702. DOI: 10.1016/S2213-2600(21)00357-X. View

10.

Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L . Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2021; 22(4):483-495. PMC: 8651254. DOI: 10.1016/S1473-3099(21)00681-2. View

11.

Munro A, Janani L, Cornelius V, Aley P, Babbage G, Baxter D . Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021; 398(10318):2258-2276. PMC: 8639161. DOI: 10.1016/S0140-6736(21)02717-3. View

12.

Thiruvengadam R, Awasthi A, Medigeshi G, Bhattacharya S, Mani S, Sivasubbu S . Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. Lancet Infect Dis. 2021; 22(4):473-482. PMC: 8616567. DOI: 10.1016/S1473-3099(21)00680-0. View

13.

Ariamanesh M, Porouhan P, PeyroShabany B, Fazilat-Panah D, Dehghani M, Nabavifard M . Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy. Cancer Invest. 2021; 40(1):26-34. PMC: 8567287. DOI: 10.1080/07357907.2021.1992420. View

14.

Javadinia S, Ariamanesh M, Nabavifard M, Porouhan P, PeyroShabany B, Fazilat-Panah D . Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic. Cancer Invest. 2021; 40(2):115-123. DOI: 10.1080/07357907.2021.1995742. View

15.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

16.

Goletti D, Petrone L, Manissero D, Bertoletti A, Rao S, Ndunda N . The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses. Clin Microbiol Infect. 2021; 27(12):1784-1789. PMC: 8272618. DOI: 10.1016/j.cmi.2021.07.005. View

17.

Abu-Raddad L, Chemaitelly H, Butt A . Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med. 2021; 385(2):187-189. PMC: 8117967. DOI: 10.1056/NEJMc2104974. View

18.

Benning L, Tollner M, Hidmark A, Schaier M, Nusshag C, Kalble F . Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers. Vaccines (Basel). 2021; 9(8). PMC: 8402499. DOI: 10.3390/vaccines9080857. View

19.

Bergamaschi C, Terpos E, Rosati M, Angel M, Bear J, Stellas D . Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep. 2021; 36(6):109504. PMC: 8299183. DOI: 10.1016/j.celrep.2021.109504. View

20.

Parry H, Bruton R, Stephens C, Bentley C, Brown K, Amirthalingam G . Extended interval BNT162b2 vaccination enhances peak antibody generation. NPJ Vaccines. 2022; 7(1):14. PMC: 8795435. DOI: 10.1038/s41541-022-00432-w. View